Cetuximab in first-line treatment of metastatic colorectal cancer in a real-life setting: Preliminary results of the EREBUS cohort.

被引：0
|
作者：
Smith, Denis
Rouyer, Magali
Mitry, Emmanuel
Monnereau, Alain
Cunha, Antonio Sa
Bignon, Emmanuelle
Le Monies, Alise
Jove, Jeremy
Noize, P.
Moore, Nicholas
Fourrier-Reglat, Annie
机构：
[1] Univ Hosp, Med Oncol, Bordeaux, France
[2] Univ V Segalen, Serv Pharmacol, Bordeaux, France
[3] Inst Curie, St Cloud, France
[4] Inst Bergonie, Bordeaux, France
[5] Chirurg Digest Hop Haut Leveque, Pessac, France
[6] Univ Bordeaux, Serv Pharmacol, Bordeaux, France
[7] Serv Pharmacol, Bordeaux, France
[8] Univ Victor Segalen, Bordeaux, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.621
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
621
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: A large Israeli retrospective cohort study
    Hammerman, Ariel
    Greenberg-Dotan, Sari
    Battat, Erez
    Feldhamer, Ilan
    Bitterman, Haim
    Brenner, Baruch
    ACTA ONCOLOGICA, 2015, 54 (02) : 164 - 170
  • [32] Phase III results for first-line treatment for metastatic colorectal cancer
    Kotsiliti, Eleni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (02) : 65 - 65
  • [33] Phase III results for first-line treatment for metastatic colorectal cancer
    Eleni Kotsiliti
    Nature Reviews Gastroenterology & Hepatology, 2023, 20 : 65 - 65
  • [34] Use of cetuximab (CTX) in first -line therapy of metastatic colorectal cancer (mCRC): Patient characteristics, safety, and effectiveness in the EREBUS cohort
    Smith, Denis
    Rouyer, Magali
    Mitry, Emmanuel
    Francois, Eric
    Monnereau, Alain
    Cunha, Antonio Sa
    Bignon, Emmanuelle
    Le Monies, Alise
    Jove, Jeremy
    Noize, Pernelle
    Moore, Nicholas
    Fourrier-Reglat, Annie
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Results of the use of oxaliplatin and capecitabine plus cetuximab as first-line therapy in the treatment of patients with metastatic colorectal cancer:: First analyses
    Barroso, S.
    Sanches, E.
    Marques, Ferreira J.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sottomayor, C.
    Espirito, Santo J.
    San-bento, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 74 - 75
  • [36] RESULTS OF THE USE OF OXALIPLATIN AND CAPECITABINE PLUS CETUXIMAB AS FIRST-LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST ANALYSES
    Barroso, S.
    Sanches, E.
    Ferreira, J. M.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sotto-Mayor, C.
    Santo, J. Espirito
    San-Bento, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 148 - 148
  • [37] A study of first-line treatments for patients with BRAFV600E mutant metastatic colorectal cancer in a real-life setting: CAPSTAN study
    Martinelli, E.
    Arnold, D.
    Tadmouri, A.
    Khan, S.
    Asselain, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S105 - S105
  • [38] COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE UNITED STATES
    Ortendahl, J. D.
    Bentley, T. G.
    Anene, A. M.
    Purdum, A. G.
    Bolinder, B.
    VALUE IN HEALTH, 2014, 17 (03) : A86 - A86
  • [39] How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
    Lindsay, Colin R.
    Roxburgh, Patricia
    Graham, Janet
    FUTURE ONCOLOGY, 2013, 9 (06) : 825 - 829
  • [40] Combination of cetuximab and chemotherapy in the first-line treatment of metastatic colorectal cancer: Slovakian experience.
    Salek, T.
    Sebo, E.
    Mazalova, D.
    Chovanec, J.
    Stresko, M.
    Thomkova, A.
    Andrasina, I.
    Barilla, R.
    Hlavata, Z.
    Mego, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345